Literature DB >> 8978275

Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease.

H Björgvinsdóttir1, C Ding, N Pech, M A Gifford, L L Li, M C Dinauer.   

Abstract

The X-linked form of chronic granulomatous disease (X-CGD), an inherited deficiency of the respiratory burst oxidase, results from mutations in the X-linked gene for gp91phox, the larger subunit of the oxidase cytochrome b. The goal of this study was to evaluate the impact of retroviral-mediated gene transfer of gp91phox on host defense against Aspergillus fumigatus in a murine model of X-CGD. Retrovirus vectors constructed using the murine stem cell virus (MSCV) backbone were used for gene transfer of the gp91phox cDNA into murine X-CGD bone marrow cells. Transduced cells were transplanted into lethally irradiated syngeneic X-CGD mice. After hematologic recovery, superoxide production, as monitored by the nitroblue tetrazolium (NBT) test, was detected in up to approximately 80% of peripheral blood neutrophils for at least 28 to 35 weeks after transplantation. Neutrophil expression of recombinant gp91phox and superoxide production were significantly less than wild-type neutrophils. However, 9 of 9 mice with approximately 50% to 80% NBT+ neutrophils after gene transfer did not develop lung disease after respiratory challenge with 150 to 500 A fumigatus spores, doses that produced disease in 16 of 16 control X-CGD mice. In X-CGD mice transplanted with mixtures of wild-type and X-CGD bone marrow, > or = 5% wild-type neutrophils were required for protection against A fumigatus challenge. These data suggest that expression of even low levels of recombinant gp91phox can substantially improve phagocyte function in X-CGD, although correction of very small percentage of phagocytes may not be sufficient for protection against A fumigatus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8978275

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  Chronic granulomatous disease.

Authors:  D Goldblatt; A J Thrasher
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

2.  TSP-1 Deficiency Alters Ocular Microbiota: Implications for Sjögren's Syndrome Pathogenesis.

Authors:  Marielle Terzulli; Laura Contreras-Ruiz; Laura Contreras Ruiz; Abirami Kugadas; Sharmila Masli; Mihaela Gadjeva
Journal:  J Ocul Pharmacol Ther       Date:  2015-05-26       Impact factor: 2.671

3.  Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease.

Authors:  H L Malech; P B Maples; N Whiting-Theobald; G F Linton; S Sekhsaria; S J Vowells; F Li; J A Miller; E DeCarlo; S M Holland; S F Leitman; C S Carter; R E Butz; E J Read; T A Fleisher; R D Schneiderman; D E Van Epps; S K Spratt; C A Maack; J A Rokovich; L K Cohen; J I Gallin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

4.  Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.

Authors:  Giorgia Santilli; Elena Almarza; Christian Brendel; Uimook Choi; Chiara Beilin; Michael P Blundell; Sneha Haria; Kathryn L Parsley; Christine Kinnon; Harry L Malech; Juan A Bueren; Manuel Grez; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

5.  Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.

Authors:  Carly G Dennis; William R Greco; Yseult Brun; Richard Youn; Harry K Slocum; Ralph J Bernacki; Russell Lewis; Nathan Wiederhold; Steven M Holland; Ruta Petraitiene; Thomas J Walsh; Brahm H Segal
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 6.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 7.  Gene therapy of chronic granulomatous disease: the engraftment dilemma.

Authors:  Manuel Grez; Janine Reichenbach; Joachim Schwäble; Reinhard Seger; Mary C Dinauer; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-11-02       Impact factor: 11.454

8.  Lentiviral Vector Gene Therapy Protects XCGD Mice From Acute Staphylococcus aureus Pneumonia and Inflammatory Response.

Authors:  Giada Farinelli; Raisa Jofra Hernandez; Alice Rossi; Serena Ranucci; Francesca Sanvito; Maddalena Migliavacca; Chiara Brombin; Aleksandar Pramov; Clelia Di Serio; Chiara Bovolenta; Bernhard Gentner; Alessandra Bragonzi; Alessandro Aiuti
Journal:  Mol Ther       Date:  2016-07-26       Impact factor: 11.454

9.  Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation.

Authors:  M A Sadat; S Dirscherl; L Sastry; J Dantzer; N Pech; S Griffin; T Hawkins; Y Zhao; C N Barese; S Cross; A Orazi; C An; W S Goebel; M C Yoder; X Li; M Grez; K Cornetta; S D Mooney; M C Dinauer
Journal:  Gene Ther       Date:  2009-12       Impact factor: 5.250

10.  Cytokine-dependent regulation of NADPH oxidase activity and the consequences for activated T cell homeostasis.

Authors:  Divya Purushothaman; Apurva Sarin
Journal:  J Exp Med       Date:  2009-06-22       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.